Pfizer Inc. CEO Ian Read wasn’t giving away any clues during the company’s second quarter sales and earnings call Aug. 2 on which way the big pharma is leaning on the issue of breaking up the business, but he did remind investors there is a possibility that it won’t happen – and that such a decision wouldn’t necessarily be a bad development for Pfizer.
A Split Won’t “Make Or Break” Pfizer, CEO Read Says
The big pharma’s chief executive assured investors there is no expiration date on optionality, suggesting the company could always reconsider splitting up the business even if decides against such action this year.
